Shatavarin I

Shatavarin I at a Glance

Shatavarin I is a steroidal saponin from the root of shatavari (Asparagus racemosus) — C₅₁H₈₆O₂₃, molecular weight 1067.2 Da, four sugars, PubChem CID 101406647, CAS 84633-36-3. It is one of a numbered series (shatavarins I through X) that gives the plant its chemical identity and its standardisation marker.

Two things about it are worth stating before anything else, because between them they account for almost the whole page.

First, shatavarin I has never been the subject of a pharmacology experiment. Not one. A PubMed title/abstract search for "shatavarin I" returns 4 records, against 24 for "shatavarin IV" — and of those four, one is the paper that determined its structure ^{3Reference 3Hayes PY et al. · 2008Steroidal saponins from the roots of Asparagus racemosusView study →}, one names it in passing as a major constituent ^{4Reference 4Onlom C et al. · 2017Immunoaffinity knockout of saponin glycosides from Asparagus racemosus to assess anti-lipid peroxidationView study →}, one is an in-silico docking exercise ^{6Reference 6Arora N · 2024Molecular docking analysis of shatavarins with female hormonal receptors — in silicoView study →}, and one is a review about shatavarin IV ^{12Reference 12Banerjee P et al. · 2025ReviewAn updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (Shatavari): with a special emphasis on shatavarin IV — reviewView study →}. There is no cell assay, no animal study, no human trial, and no isolated-molecule measurement of any biological activity. Nearly everything written about “the shatavarins” is a result for shatavarin IV, or for a mixed saponin fraction, being generalised backwards.

Second, the name is unreliable. The structures originally published for shatavarins I and IV were both wrong — the glycosidic linkages were misassigned — and were corrected only in 2006 ^{1Reference 1Hayes PY et al. · 2006Structural revision of shatavarins I and IV, the major components from the roots of Asparagus racemosusView study →}. In the same year the same group had to untangle four parallel naming series (asparinins, asparosides, curillins, curillosides and shatavarins) that had been applied to overlapping sets of the same molecules ^{2Reference 2Hayes PY et al. · 2006Asparinins, asparosides, curillins, curillosides and shavatarins: structural clarification with the isolation of shatavarin V, a new steroidal saponin from the root of Asparagus racemosusView study →}. Shatavarin I is also asparoside B ^{3Reference 3Hayes PY et al. · 2008Steroidal saponins from the roots of Asparagus racemosusView study →}. That is not a footnote; it means a pre-2006 paper naming “shatavarin I” may not be describing the molecule described here.

What shatavarin I is, structurally, is genuinely useful to know: it is the furostanol form of shatavarin IV. Strip its C-26 glucose and the F ring snaps shut and you have shatavarin IV exactly. That single relationship explains its behaviour in the plant, in a drying shed and — as far as anyone can infer — in the gut.

The Nomenclature Problem

This is the most useful thing on the page, so it goes first.

Between roughly 1970 and 2000, at least four independent research programmes isolated steroidal saponins from Asparagus species and gave them four incompatible naming systems: asparinins, asparosides, curillins/curillosides, and shatavarins. Several of the resulting names turned out to describe the same molecule. In 2006, Hayes and colleagues at the University of Queensland re-isolated the major A. racemosus saponins by RP-HPLC, determined their structures by 1D and 2D NMR, and published two corrections in the same year:

Paper	What it fixed
Structural revision of shatavarins I and IV (2006) 1Reference 1Hayes PY et al. · 2006Structural revision of shatavarins I and IV, the major components from the roots of Asparagus racemosusView study →	The published structures of both major shatavarins were incorrect — the glycosidic linkages had been wrongly assigned. Revised structures given for each.
Asparinins, asparosides, curillins, curillosides and shavatarins: structural clarification (2006) 2Reference 2Hayes PY et al. · 2006Asparinins, asparosides, curillins, curillosides and shavatarins: structural clarification with the isolation of shatavarin V, a new steroidal saponin from the root of Asparagus racemosusView study →	Reconciled the four naming series against each other, and isolated shatavarin V as new.

The 2008 follow-up, which added shatavarins VI–X, states the equivalences explicitly: shatavarin I is asparoside B, shatavarin IV is asparinin B, and schidigerasaponin D5 is asparanin A ^{3Reference 3Hayes PY et al. · 2008Steroidal saponins from the roots of Asparagus racemosusView study →}.

And it is still not settled. PubChem lists shatavarin IV’s synonyms as asparanin B and curillin H — not asparinin B, which is what the primary structural paper calls it ^{3Reference 3Hayes PY et al. · 2008Steroidal saponins from the roots of Asparagus racemosusView study →}. So for the best-studied molecule in the series, the chemical databases and the definitive isolation literature disagree about which alias belongs to it. Shatavarin I, being less studied, simply carries fewer aliases and therefore fewer contradictions.

The practical consequences:

• A roman numeral in this series is not a stable identifier. Verify against a structure or a CAS/PubChem record, not against the name.
• Pre-2006 literature is suspect on structure, though not necessarily on the presence or amount of “a saponin”.
• The series numbering carries no meaning. Shatavarin I is not the first-discovered, the most abundant, or the most active. It is a label.

Shatavarin I vs. Shatavarin IV

These two are not alternatives; they are two states of one steroid skeleton, and the difference is a single sugar.

	Shatavarin I	Shatavarin IV
Type	Furostanol — F ring open, C-22 hydroxyl	Spirostanol — F ring closed as a spiroketal
Glycosylation	Bidesmosidic — two sugar chains	Monodesmosidic — one sugar chain
Sugars	Rha-(1→4)[Glc-(1→2)]-Glc at C-3, plus Glc at C-26	Rha-(1→4)[Glc-(1→2)]-Glc at C-3 only
Formula / mass	C₅₁H₈₆O₂₃ · 1067.2 Da	C₄₅H₇₄O₁₇ · 887.1 Da
Aglycone on full hydrolysis	Sarsasapogenin	Sarsasapogenin
CAS	84633-36-3	84633-34-1
PubChem CID	101406647	441896

Remove the C-26 glucose from shatavarin I and the resulting 22,26-diol cyclises spontaneously, losing water, to give shatavarin IV. This is the same relationship that protodioscin has to dioscin, and it is the standard furostanol/spirostanol pair found throughout the steroidal saponins.

Three things follow from it, and all three are more informative than anything in the pharmacology literature.

1. The ratio in a product is partly a processing artefact. In living plant tissue, furostanol glycosides are the stored form. On harvest, drying and storage, a plant β-glucosidase — furostanol glycoside 26-O-β-glucosidase (F26G), characterised from Costus speciosus rhizomes and highly specific for the C-26 glucose — converts them to the spirostanol counterparts ^{9Reference 9Inoue K · 1996Purification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomesView study →}. So a root that was rich in shatavarin I when it came out of the ground can be rich in shatavarin IV by the time it is assayed, depending entirely on how it was dried. Nobody has measured this for A. racemosus, but it is the default expectation for the class and it should temper any claim about the “natural” shatavarin I : IV ratio.

2. Shatavarin I should be the less membrane-active of the two. Saponins are surfactants, and a great deal of the “cytotoxic at X µM” literature in this class is membrane disruption rather than pharmacology. But that behaviour tracks structure: bidesmosidic saponins are essentially non-haemolytic — quinoa bidesmosidic saponins showed no haemolysis at 500 µg/mL, while their monodesmosidic hydrolysis products degraded erythrocytes at 20 µg/mL, a ≥25-fold shift ^{10Reference 10Savarino P et al. · 2022Impact of the hydrolysis and methanolysis of bidesmosidic Chenopodium quinoa saponins on their hemolytic activityView study →}. Bidesmosidic forms are described as the “dormant” form of the saponin in the plant. Shatavarin I is bidesmosidic; shatavarin IV is monodesmosidic. If shatavarin IV’s cytotoxicity results are partly membranolytic artefact, shatavarin I is the molecule least likely to reproduce them.

3. Both converge on the same aglycone anyway. Sarsasapogenin — (25S)-5β-spirostan-3β-ol, C₂₇H₄₄O₃, 416.6 Da — is what survives full deglycosylation, and it is the only species on this chain small enough to plausibly cross a gut wall.

Where It Sits on the Gut-Hydrolysis Chain

Steroidal saponins of this size are not absorbed intact. The exposure that matters is the deglycosylated aglycone produced by gut bacteria, and for the shatavarins that is sarsasapogenin.

Shatavarin I  ──(−C-26 Glc, ring closure)──►  Shatavarin IV  ──(−trisaccharide)──►  Sarsasapogenin
  1067 Da, 4 sugars                             887 Da, 3 sugars                      417 Da, 0 sugars
  bidesmosidic furostanol                       monodesmosidic spirostanol            free aglycone

Shatavarin I sits at the far end of that chain — the largest, most glycosylated, least absorbable species in the series. The relevant enzymology is established: bacterial GH3 β-glucosidases from the human gut, such as BlBG3 from Bifidobacterium longum, hydrolyse furostanol glycosides efficiently ^{11Reference 11Yan S et al. · 2018Functional and structural characterization of a β-glucosidase involved in saponin metabolism from intestinal bacteriaView study →}, and F26G-type activity does the same job in plant tissue ^{9Reference 9Inoue K · 1996Purification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomesView study →}.

The one direct piece of evidence on absorption comes from a 2026 scale-up isolation of six A. racemosus saponins and sapogenins, which ran SwissADME predictions across them. The aglycone derivatives (diosgenin, sarsasapogenin) showed the greatest predicted absorption, while the highly glycosylated saponins showed low permeability, with Abbott bioavailability scores of 0.17 and topological polar surface areas ≥167 Ų ^{8Reference 8D C D et al. · 2026Scale-up isolation of high-purity shatavarins from Asparagus racemosus via flash chromatography with bioavailability and pharmacological insightsView study →}. Shatavarin I was not among the six compounds isolated — but with four sugars and a mass of 1067 Da it is larger and more polar than any of them, so the direction is not in doubt. The authors are careful to note their models give relative comparisons, not validated oral bioavailability.

The practical upshot: any in-vitro concentration reported for a shatavarin is unlikely to be reachable in plasma by the oral route. Whatever shatavari does systemically, it probably does through sarsasapogenin and other small metabolites, not through shatavarin I.

What It's Used For

There is no pharmacology of shatavarin I. This section exists to make that precise rather than to fill space.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row below is capped at the bottom of the scale on purpose: not one of these applications has been tested on isolated shatavarin I. The scores measure how much the claim has been examined for this specific molecule, which is close to zero in all four cases. Each application links to its write-up.

01Hormone-Receptor BindingShaky8%One in-silico docking paper covering seven shatavarins ^{6Reference 6Arora N · 2024Molecular docking analysis of shatavarins with female hormonal receptors — in silicoView study →}

02ImmunomodulationShaky8%Tissue-culture “shatavarins” as an undifferentiated mixture ^{17Reference 17Pise MV et al. · 2015In vitroImmunomodulatory potential of shatavarins produced from Asparagus racemosus tissue cultures — in vitroView study →}

03AntiproliferativeShaky5%Other A. racemosus saponins; shatavarin I never tested ^{14Reference 14Onlom C et al. · 2017In vitroPreparative and rapid purification of saponins from Asparagus racemosus root by high performance centrifugal partition chromatography — in vitroView study →}

04AntioxidantShaky3%A fraction-level result that came out negative ^{4Reference 4Onlom C et al. · 2017Immunoaffinity knockout of saponin glycosides from Asparagus racemosus to assess anti-lipid peroxidationView study →}

Mechanisms

Pharmacokinetics

There is no pharmacokinetic study of shatavarin I — no Cmax, no half-life, no absorption measurement, no metabolite identification, in any species. What can be said is inference from structure and from class behaviour, and it points one way.

At 1067 Da with four sugars, shatavarin I is at the extreme end of the steroidal-saponin range for size and polarity. In the one ADME modelling exercise run on A. racemosus compounds, the highly glycosylated saponins — all smaller than this one — scored 0.17 on the Abbott bioavailability scale with TPSA ≥167 Ų, while the free aglycones scored far better ^{8Reference 8D C D et al. · 2026Scale-up isolation of high-purity shatavarins from Asparagus racemosus via flash chromatography with bioavailability and pharmacological insightsView study →}. Steroidal saponins that are not absorbed in the small intestine reach the colon, where bacterial glycosidases strip the sugars: BlBG3, a GH3 β-glucosidase cloned from human stool Bifidobacterium longum, hydrolyses furostanol glycosides more efficiently than other characterised microbial β-glucosidases ^{11Reference 11Yan S et al. · 2018Functional and structural characterization of a β-glucosidase involved in saponin metabolism from intestinal bacteriaView study →}.

So the most likely fate of an oral dose of shatavarin I is: lose the C-26 glucose → become shatavarin IV → lose the trisaccharide → become sarsasapogenin, with the aglycone as the species that actually reaches tissue. Every step of that is plausible and none of it has been demonstrated for this molecule specifically. Treat it as the working model, not a finding.

Clinical Trials

None, under any name. There is no registered study of shatavarin I, and no trial has ever administered it. The human shatavari literature uses standardised whole-root extracts at gram doses — for instance 1000 mg/day for six weeks in a 20-participant randomised double-blind trial in postmenopausal women, which improved handgrip strength and vastus lateralis myosin regulatory light-chain phosphorylation but did not alter bone-turnover markers ^{16Reference 16O’Leary MF et al. · 2021RCTShatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light chain phosphorylation but does not alter markers of bone turnover — randomised controlled trialView study →}.

Last checked: August 2026.

The Hormone Claim, Handled Properly

Shatavari is sold as a hormone-balancing herb, and the saponins are what the marketing points at. The chemistry needs stating plainly, because the same error recurs across every steroidal-sapogenin supplement.

A steroid skeleton is not a steroid hormone, and the body cannot make one from the other. Sapogenins like sarsasapogenin and diosgenin are industrial feedstocks — the Marker degradation converts diosgenin to progesterone in a factory, through a sequence of chemical steps involving acetic anhydride, oxidation and pyrolysis. There is no human enzymatic route from a sapogenin to progesterone, DHEA or testosterone. The wild-yam-converts-to-progesterone claim is false, and topical “natural progesterone” creams that work do so because progesterone was added to them. Shatavarin I’s aglycone is sarsasapogenin, and the same rule applies without modification.

That does not rule out a direct hormonal action. Direct binding to an oestrogen receptor, or modulation of a steroidogenic enzyme, would be a legitimate and different claim. For shatavarin I, that claim currently rests on docking scores and nothing else ^{6Reference 6Arora N · 2024Molecular docking analysis of shatavarins with female hormonal receptors — in silicoView study →}. Reviews describe the shatavarins collectively as phytoestrogenic ^{12,13Reference 12Banerjee P et al. · 2025ReviewAn updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (Shatavari): with a special emphasis on shatavarin IV — reviewView study →Reference 13Kurmi A et al. · 2026ReviewModulation of various pharmacological pathways by Asparagus saponins: special emphasis on shatavarin-IV — reviewView study →}, but that description traces back to whole-extract and shatavarin IV work, not to any measurement on this molecule.

The honest position: shatavari may well have oestrogen-like effects — the postmenopausal muscle-function trial is at least consistent with it ^{16Reference 16O’Leary MF et al. · 2021RCTShatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light chain phosphorylation but does not alter markers of bone turnover — randomised controlled trialView study →} — but nothing published attributes them to shatavarin I, and no mechanism for shatavarin I has been measured.

Isolate vs. Plant

The isolate/plant boundary here is unusually stark: there is no isolate literature at all.

Every biological claim ever made in the vicinity of shatavarin I rests on one of three things — a whole A. racemosus extract ^{4,7,16Reference 4Onlom C et al. · 2017Immunoaffinity knockout of saponin glycosides from Asparagus racemosus to assess anti-lipid peroxidationView study →Reference 7Borse SP · 2015In vitroEffects of Ayurvedic Rasayana botanicals on CYP3A4 isoenzyme system — in vitroView study →Reference 16O’Leary MF et al. · 2021RCTShatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light chain phosphorylation but does not alter markers of bone turnover — randomised controlled trialView study →}, a mixed saponin fraction ^{4,17Reference 4Onlom C et al. · 2017Immunoaffinity knockout of saponin glycosides from Asparagus racemosus to assess anti-lipid peroxidationView study →Reference 17Pise MV et al. · 2015In vitroImmunomodulatory potential of shatavarins produced from Asparagus racemosus tissue cultures — in vitroView study →}, or a different molecule, almost always shatavarin IV ^{12,13Reference 12Banerjee P et al. · 2025ReviewAn updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (Shatavari): with a special emphasis on shatavarin IV — reviewView study →Reference 13Kurmi A et al. · 2026ReviewModulation of various pharmacological pathways by Asparagus saponins: special emphasis on shatavarin-IV — reviewView study →}. The molecule’s own literature consists of structure determination ^{1,2,3Reference 1Hayes PY et al. · 2006Structural revision of shatavarins I and IV, the major components from the roots of Asparagus racemosusView study →Reference 2Hayes PY et al. · 2006Asparinins, asparosides, curillins, curillosides and shavatarins: structural clarification with the isolation of shatavarin V, a new steroidal saponin from the root of Asparagus racemosusView study →Reference 3Hayes PY et al. · 2008Steroidal saponins from the roots of Asparagus racemosusView study →} and constituent lists.

This creates a specific and very common failure mode, which the reader should be armed against. Shatavarin IV is the plant’s marker compound — the thing used to standardise and authenticate the root — so it attracts the analytical attention and, over time, the pharmacological attention too. Reviews then generalise from “shatavarin IV does X” to “the shatavarins do X” to “shatavari’s saponins do X,” and a reader arriving at shatavarin I inherits the whole chain without a single measurement underneath it. The chain breaks at the first link: shatavarin I and IV are chemically different (bidesmosidic furostanol vs. monodesmosidic spirostanol), and that difference is exactly the one that governs membrane activity and absorption.

Where the two molecules can legitimately be treated together is downstream of gut hydrolysis, since both give sarsasapogenin. Any effect that belongs to the aglycone belongs to both. Any effect that belongs to the intact glycoside belongs to neither until it is measured.

Prevalence in Nature

Shatavarin I is reported from the roots of Asparagus racemosus, which is the only source with published structural work ^{1,2,3Reference 1Hayes PY et al. · 2006Structural revision of shatavarins I and IV, the major components from the roots of Asparagus racemosusView study →Reference 2Hayes PY et al. · 2006Asparinins, asparosides, curillins, curillosides and shavatarins: structural clarification with the isolation of shatavarin V, a new steroidal saponin from the root of Asparagus racemosusView study →Reference 3Hayes PY et al. · 2008Steroidal saponins from the roots of Asparagus racemosusView study →}. It is named alongside shatavarin IV as one of the two major saponin glycosides of the root ^{4,12Reference 4Onlom C et al. · 2017Immunoaffinity knockout of saponin glycosides from Asparagus racemosus to assess anti-lipid peroxidationView study →Reference 12Banerjee P et al. · 2025ReviewAn updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (Shatavari): with a special emphasis on shatavarin IV — reviewView study →}.

No concentration figure has ever been published for it. Not a mg/g, not a percentage of dry weight, not a percentage of extract — in any tissue, in any accession, in any species. No concentration chart is shown for that reason. What exists is context:

• Total saponin glycosides in A. racemosus roots range from undetectable to about 12 mg/g dry weight across accessions from four Thai provinces and one Indian sample — a range wide enough to include zero ^{5Reference 5Onlom C et al. · 2017Quantification of saponins in Asparagus racemosus by HPLC-Q-TOF-MS/MSView study →}. Saponins were detected predominantly in roots rather than leaves or stems.
• The five saponins that validated method actually quantifies are asparacoside, shatavarin IX, shatavarin IV, asparanin A and shatavarin V. Shatavarin I is not one of them ^{5Reference 5Onlom C et al. · 2017Quantification of saponins in Asparagus racemosus by HPLC-Q-TOF-MS/MSView study →}.
• Shatavarin IV, by comparison, has been quantified repeatedly and varies enormously: 152 µg/g in the best of twelve elite Indian accessions, up to 4.68 mg/g in A. adscendens roots by HPTLC, and 0.36–3.42% w/w in commercial dry extracts depending on preparation ^{18Reference 18Mawal P et al. · 2026Comparative HPTLC analysis of shatavarin IV, sarsasapogenin, caffeic acid, β-sitosterol and lupeol in roots and cladodes of ten Asparagus L. ssp. from North IndiaView study →}.
• Metabolic profiling of A. racemosus by LC-MS identified 33 steroidal saponins across the plant, with 153 transcripts annotated to steroidal-saponin biosynthesis in root, leaf and fruit transcriptomes ^{15Reference 15Srivastava PL et al. · 2018Comprehensive metabolic and transcriptomic profiling of various tissues provide insights for saponin biosynthesis in the medicinally important Asparagus racemosusView study →}. The saponin pool is large and the named members are a small labelled subset of it.

Because shatavarin I is the furostanol precursor, its measured abundance in dried material will also depend on how much F26G-type conversion happened after harvest ^{9Reference 9Inoue K · 1996Purification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomesView study →} — a variable nobody has controlled for in this species. Any future quantification of shatavarin I that does not record drying and storage conditions should be read with that in mind.

Its Role in Plants

Bidesmosidic furostanol glycosides are widely understood as the stored, inactive form of a plant’s saponin arsenal. The second sugar chain keeps the molecule water-soluble and, critically, non-membranolytic, so the plant can accumulate it in living tissue without damaging its own cells ^{10Reference 10Savarino P et al. · 2022Impact of the hydrolysis and methanolysis of bidesmosidic Chenopodium quinoa saponins on their hemolytic activityView study →}. On wounding, harvest or senescence, the C-26 glucose is removed by a specific β-glucosidase and the molecule converts to the spirostanol form, which is membrane-active ^{9Reference 9Inoue K · 1996Purification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomesView study →}.

That is a chemical-defence design: a harmless precursor stored in bulk, activated by an enzyme released on tissue damage. It is the same logic as the glucosinolate/myrosinase and cyanogenic-glycoside systems, executed with a steroid. On this reading shatavarin I is not shatavari’s “active saponin” at all — it is the magazine, and shatavarin IV is the round.

This is an inference from well-established class behaviour, not something demonstrated in A. racemosus; the F26G work was done in Costus speciosus and Solanum torvum ^{9Reference 9Inoue K · 1996Purification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomesView study →}. But it is consistent with the transcriptomic picture of an elaborate steroidal-saponin biosynthetic apparatus concentrated in the root ^{15Reference 15Srivastava PL et al. · 2018Comprehensive metabolic and transcriptomic profiling of various tissues provide insights for saponin biosynthesis in the medicinally important Asparagus racemosusView study →}.

Discovery & Synthesis

Shatavarin I was described from Asparagus racemosus root in the 1980s — its CAS number, 84633-36-3, sits immediately alongside shatavarin IV’s 84633-34-1, placing both registrations in the same block of Indian phytochemical work on the plant (the Chemistry of Ayurvedic Crude Drugs programme that produced shatavarin IV). The name is simply a serial label within the shatavarin series; it carries no structural or historical meaning, and in particular the numeral does not indicate priority, abundance or activity.

The structure published at that time was incorrect. Hayes, Jahidin, Lehmann, Penman, Kitching and De Voss re-isolated the two major saponins by RP-HPLC and showed by extensive 1D and 2D NMR that the previously reported glycosidic linkages were misassigned for both shatavarin I and shatavarin IV ^{1Reference 1Hayes PY et al. · 2006Structural revision of shatavarins I and IV, the major components from the roots of Asparagus racemosusView study →}. The revised structure of shatavarin I is a (22R,25S)-26-O-β-D-glucopyranosyl-22-hydroxy-5β-furostan-3β-yl 6-deoxy-α-L-mannopyranosyl-(1→4)-[β-D-glucopyranosyl-(1→2)]-β-D-glucopyranoside — a rhamnose–glucose–glucose branched trisaccharide at C-3, plus a single glucose at C-26 (PubChem CID 101406647). The same group’s companion paper reconciled the competing asparinin/asparoside/curillin/curilloside nomenclature and added shatavarin V ^{2Reference 2Hayes PY et al. · 2006Asparinins, asparosides, curillins, curillosides and shavatarins: structural clarification with the isolation of shatavarin V, a new steroidal saponin from the root of Asparagus racemosusView study →}; their 2008 paper added shatavarins VI–X and recorded the shatavarin I = asparoside B equivalence ^{3Reference 3Hayes PY et al. · 2008Steroidal saponins from the roots of Asparagus racemosusView study →}.

There is no total synthesis of shatavarin I, and none should be expected — a four-sugar bidesmosidic steroidal glycoside is a demanding synthetic target with no commercial reason to attempt it. All material described in the literature came from column chromatography, RP-HPLC or centrifugal partition chromatography of root extract ^{1,3,14Reference 1Hayes PY et al. · 2006Structural revision of shatavarins I and IV, the major components from the roots of Asparagus racemosusView study →Reference 3Hayes PY et al. · 2008Steroidal saponins from the roots of Asparagus racemosusView study →Reference 14Onlom C et al. · 2017In vitroPreparative and rapid purification of saponins from Asparagus racemosus root by high performance centrifugal partition chromatography — in vitroView study →}. No commercial analytical standard is generally available, which is part of why the molecule is not routinely quantified ^{5Reference 5Onlom C et al. · 2017Quantification of saponins in Asparagus racemosus by HPLC-Q-TOF-MS/MSView study →}. Patents: not yet researched.

Toxicity & Safety

The honest verdict is not characterised. There has never been a toxicology study of shatavarin I — no acute toxicity, no genotoxicity, no reproductive or developmental work, no animal experiment of any kind. The low grading reflects three things, none of which is a safety demonstration: the long history of human consumption of shatavari root, the poor absorption of a 1067 Da tetraglycoside ^{8Reference 8D C D et al. · 2026Scale-up isolation of high-purity shatavarins from Asparagus racemosus via flash chromatography with bioavailability and pharmacological insightsView study →}, and the structure–activity expectation that a bidesmosidic saponin is the non-haemolytic form of its pair ^{10Reference 10Savarino P et al. · 2022Impact of the hydrolysis and methanolysis of bidesmosidic Chenopodium quinoa saponins on their hemolytic activityView study →}.

Safety at a Glance

✅ Low / no toxicity

• Bidesmosidic saponins are the non-membranolytic form. Quinoa bidesmosidic saponins showed no haemolysis at 500 µg/mL; their monodesmosidic products lysed erythrocytes at 20 µg/mL ^{10Reference 10Savarino P et al. · 2022Impact of the hydrolysis and methanolysis of bidesmosidic Chenopodium quinoa saponins on their hemolytic activityView study →}. Shatavarin I is the bidesmosidic one.
• Poor absorption caps systemic exposure. At 1067 Da with four sugars it is larger and more polar than the A. racemosus saponins already predicted to have low permeability ^{8Reference 8D C D et al. · 2026Scale-up isolation of high-purity shatavarins from Asparagus racemosus via flash chromatography with bioavailability and pharmacological insightsView study →}.
• No CYP3A4 inhibition at the extract level. An aqueous A. racemosus extract characterised for shatavarins I and IV showed IC₅₀ > 1000 µg/mL against CYP3A4 in rat liver microsomes, against ketoconazole at 0.036 µg/mL ^{7Reference 7Borse SP · 2015In vitroEffects of Ayurvedic Rasayana botanicals on CYP3A4 isoenzyme system — in vitroView study →}.
• No toxicology data exist for this molecule at all. Absence of a signal here is absence of looking, not evidence of safety.
• No reproductive or developmental data. This matters more than usual because shatavari is used specifically in pregnancy, lactation and postpartum contexts — that decision belongs on the herb page, where the preparation and dose are known, not on a molecule with zero data.
• Saponins are surfactants. The class irritates mucous membranes and lyses erythrocytes on direct contact; a purified or parenteral preparation of any saponin should not be assumed benign because the whole root is well tolerated.
• The hormone-modulation question is unresolved, not settled safe. Shatavari extracts are used for oestrogen-sensitive indications and the shatavarins are the proposed mediators ^{12,13Reference 12Banerjee P et al. · 2025ReviewAn updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (Shatavari): with a special emphasis on shatavarin IV — reviewView study →Reference 13Kurmi A et al. · 2026ReviewModulation of various pharmacological pathways by Asparagus saponins: special emphasis on shatavarin-IV — reviewView study →}. Nothing has been measured for shatavarin I in either direction.

Full Safety & Interactions Detail

No adverse effect of shatavarin I has been reported, and no study has been designed to look for one. Reasoning has to run from class behaviour and from extract-level data.

Drug interactions. The single relevant measurement is at the extract level: Borse and Kamble prepared an aqueous A. racemosus extract per the Ayurvedic Pharmacopoeia of India, characterised it by HPLC and mass spectrometry for the presence of shatavarins IV and I, and assayed it against CYP3A4 using a testosterone 6β-hydroxylation probe in rat liver microsomes. No inhibition was seen up to IC₅₀ > 1000 µg/mL, while the positive control ketoconazole abolished activity at 0.531 µg/mL (IC₅₀ 0.036 µg/mL) ^{7Reference 7Borse SP · 2015In vitroEffects of Ayurvedic Rasayana botanicals on CYP3A4 isoenzyme system — in vitroView study →}. That is reassuring for the preparation tested and says nothing about induction, about other CYP isoforms, about P-glycoprotein, or about the isolated molecule. No transporter study exists.

Membrane activity. Saponins as a class are surfactants that intercalate into cholesterol-containing membranes, which is why haemolysis is the standard screening assay for them. The structure–activity rule is well established and works in shatavarin I’s favour: bidesmosidic forms are the “dormant” storage form, and haemolytic activity appears when the second sugar chain is removed ^{10Reference 10Savarino P et al. · 2022Impact of the hydrolysis and methanolysis of bidesmosidic Chenopodium quinoa saponins on their hemolytic activityView study →}. Removing shatavarin I’s C-26 glucose gives shatavarin IV, the more membrane-active molecule — so the safety-relevant question for a shatavari product is not how much shatavarin I it contains, but how much has already converted ^{9Reference 9Inoue K · 1996Purification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomesView study →}.

Populations and pregnancy. No data. Shatavari is traditionally given as a galactagogue and reproductive tonic ^{13Reference 13Kurmi A et al. · 2026ReviewModulation of various pharmacological pathways by Asparagus saponins: special emphasis on shatavarin-IV — reviewView study →}, which means the population most likely to consume it is the population with the least toxicological information about its constituents. That verdict belongs on the herb monograph where the preparation and dose are defined; at the molecule level the only accurate statement is that nothing has been studied.

A note on the cytotoxicity literature generally. Where A. racemosus saponins have been tested against carcinoma lines, at least one study did report the normally-missing selectivity check against normal cells — IC₅₀ 14–37 µM on carcinoma lines vs. 22–66 µM on primary human fibroblasts ^{14Reference 14Onlom C et al. · 2017In vitroPreparative and rapid purification of saponins from Asparagus racemosus root by high performance centrifugal partition chromatography — in vitroView study →}. A margin of roughly 1.5–2× is thin, and consistent with a substantial non-selective membrane component. Shatavarin I was not tested, and should not inherit either the activity or the concern.

Dosage

There is no dose. Shatavarin I has never been given to a human being or an animal as an isolate, no bioassay has ever established an active concentration for it, and no analytical standard is in routine use. There is nothing to convert into an intake.

Real-world exposure comes only from shatavari root preparations, where it is one unquantified saponin among at least 33 ^{15Reference 15Srivastava PL et al. · 2018Comprehensive metabolic and transcriptomic profiling of various tissues provide insights for saponin biosynthesis in the medicinally important Asparagus racemosusView study →}, inside a saponin fraction whose total content ranges from undetectable to ~12 mg/g dry weight ^{5Reference 5Onlom C et al. · 2017Quantification of saponins in Asparagus racemosus by HPLC-Q-TOF-MS/MSView study →}, and whose furostanol/spirostanol split depends on how the root was dried ^{9Reference 9Inoue K · 1996Purification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomesView study →}. Product standardisation targets shatavarin IV, not I — so even a “standardised to X% shatavarins” label carries no information about this molecule.

For what the herb itself has been given at in a controlled setting: 1000 mg/day of standardised root extract for six weeks in postmenopausal women ^{16Reference 16O’Leary MF et al. · 2021RCTShatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light chain phosphorylation but does not alter markers of bone turnover — randomised controlled trialView study →}. That is a herb dose, not a molecule dose, and it appears here only to show the scale of the gap. Nothing here is a recommendation.

References

1. Hayes PY, Jahidin AH, Lehmann R, Penman K, Kitching W, De Voss JJ (2006). Structural revision of shatavarins I and IV, the major components from the roots of Asparagus racemosus. Tetrahedron Letters 47(39):6965–6969. https://doi.org/10.1016/j.tetlet.2006.07.121
2. Hayes PY, Jahidin AH, Lehmann R, Penman K, Kitching W, De Voss JJ (2006). Asparinins, asparosides, curillins, curillosides and shavatarins: structural clarification with the isolation of shatavarin V, a new steroidal saponin from the root of Asparagus racemosus. Tetrahedron Letters 47(49):8683–8687. https://doi.org/10.1016/j.tetlet.2006.10.030
3. Hayes PY, Jahidin AH, Lehmann R, Penman K, Kitching W, De Voss JJ (2008). Steroidal saponins from the roots of Asparagus racemosus. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/17936315/
4. Onlom C, Phrompittayarat W, Putalun W, Waranuch N, Ingkaninan K (2017). Immunoaffinity knockout of saponin glycosides from Asparagus racemosus to assess anti-lipid peroxidation. Phytochemical Analysis. https://pubmed.ncbi.nlm.nih.gov/28198114/
5. Onlom C, Nuengchamnong N, Phrompittayarat W, Putalun W, Waranuch N, Ingkaninan K (2017). Quantification of saponins in Asparagus racemosus by HPLC-Q-TOF-MS/MS. Natural Product Communications. https://pubmed.ncbi.nlm.nih.gov/30549812/
6. Arora N, Banerjee AK (2024). Molecular docking analysis of shatavarins with female hormonal receptors — in silico. Bioinformation. https://pubmed.ncbi.nlm.nih.gov/39309564/
7. Borse SP, Kamble BB (2015). Effects of Ayurvedic Rasayana botanicals on CYP3A4 isoenzyme system — in vitro. Journal of Integrative Medicine. https://pubmed.ncbi.nlm.nih.gov/26006029/
8. D C D, Girme A, Salvankar K, Chinchansure A, Ranjan R, N L YK, R EJ, Mundkinajeddu D (2026). Scale-up isolation of high-purity shatavarins from Asparagus racemosus via flash chromatography with bioavailability and pharmacological insights. ACS Omega. https://pubmed.ncbi.nlm.nih.gov/41970898/
9. Inoue K, Ebizuka Y (1996). Purification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomes. FEBS Letters. https://pubmed.ncbi.nlm.nih.gov/8549824/
10. Savarino P, Contino C, Colson E, Cabrera-Barjas G, De Winter J, Gerbaux P (2022). Impact of the hydrolysis and methanolysis of bidesmosidic Chenopodium quinoa saponins on their hemolytic activity. Molecules. https://pubmed.ncbi.nlm.nih.gov/35630692/
11. Yan S, Wei PC, Chen Q, Chen X, Wang SC, Li JR, Gao C (2018). Functional and structural characterization of a β-glucosidase involved in saponin metabolism from intestinal bacteria. Biochemical and Biophysical Research Communications. https://pubmed.ncbi.nlm.nih.gov/29421652/
12. Banerjee P, Das A, Kumar P, Chakraborty S, Jalan K (2025). An updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (Shatavari): with a special emphasis on shatavarin IV — review. Journal of the American Nutrition Association. https://pubmed.ncbi.nlm.nih.gov/40334116/
13. Kurmi A, Fatima E, Negi AS, Saikia D (2026). Modulation of various pharmacological pathways by Asparagus saponins: special emphasis on shatavarin-IV — review. Chemistry & Biodiversity. https://pubmed.ncbi.nlm.nih.gov/41370308/
14. Onlom C, Yang Y, Aisa HA, Woranuch N, Phrompittayarat W, Putalun W, Ingkaninan K (2017). Preparative and rapid purification of saponins from Asparagus racemosus root by high performance centrifugal partition chromatography — in vitro. Natural Product Communications. https://pubmed.ncbi.nlm.nih.gov/30428221/
15. Srivastava PL, Shukla A, Kalunke RM (2018). Comprehensive metabolic and transcriptomic profiling of various tissues provide insights for saponin biosynthesis in the medicinally important Asparagus racemosus. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/29904061/
16. O’Leary MF, Jackman SR, Sabou VR, Campbell MI, Tang JCY, Dutton J, Bowtell JL (2021). Shatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light chain phosphorylation but does not alter markers of bone turnover — randomised controlled trial. Nutrients. https://pubmed.ncbi.nlm.nih.gov/34959836/
17. Pise MV, Rudra JA, Upadhyay A (2015). Immunomodulatory potential of shatavarins produced from Asparagus racemosus tissue cultures — in vitro. Journal of Natural Science, Biology and Medicine. https://pubmed.ncbi.nlm.nih.gov/26283842/
18. Mawal P, Kapoor M, Pradhan SK, Rani J, Gupta RC (2026). Comparative HPTLC analysis of shatavarin IV, sarsasapogenin, caffeic acid, β-sitosterol and lupeol in roots and cladodes of ten Asparagus L. ssp. from North India. Natural Product Research. https://pubmed.ncbi.nlm.nih.gov/39319375/

View all 18 references▾